stockrow
Friday 6 November 2026
Export TNYA’s income statement to Excel — free account
Tenaya Therapeutics, Inc.
TNYA Healthcare Biotechnology
- EPS
- +30.2%
- Free cash flow
- −13.2%
Quarter to September 2026, against a year earlier
0.36
0.04
+12.50%
Follow TNYA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 3 | 279 | +736.2% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (26) | (38) | (73) | (124) | (124) | (111) | (91) | (102) | +22.9% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (26) | (38) | (73) | (124) | (124) | (111) | (91) | (102) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (34.70) | (39.50) | (4.10) | (2.76) | (1.68) | (1.31) | (0.59) | (0.49) | (49.3%) | ||||||
| Cash flow | — | — | — | (31.87) | (36.47) | (3.43) | (2.33) | (1.38) | (1.07) | (0.45) | (0.24) | (50.9%) | ||||||
| Capex | — | — | — | (3.87) | (10.04) | (1.42) | (0.46) | (0.02) | (0.01) | 0.00 | 0.00 | (68.2%) | ||||||
| Free cash flow | — | — | — | (35.74) | (46.51) | (4.85) | (2.79) | (1.40) | (1.08) | (0.45) | (0.24) | (51.8%) | ||||||
| Book value | — | — | — | 38.76 | 143.46 | 15.71 | 5.43 | 1.89 | 1.09 | 0.81 | 0.24 | (47.6%) | ||||||
| Shares, m | — | — | — | 1 | 1 | 18 | 45 | 74 | 85 | 153 | 203 | +142.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (24) | (35) | (61) | (104) | (102) | (91) | (68) | (54) | +19.0% | |||||
| Capex | — | — | — | (3) | (10) | (25) | (21) | (1) | (1) | (1) | 0 | (22.8%) | ||||||
| Free cash flow | — | — | — | (27) | (45) | (86) | (125) | (103) | (92) | (69) | (55) | +16.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 24 | 125 | 234 | 170 | 89 | 51 | 90 | 52 | +25.0% | |||||
| Net debt | — | — | — | (27) | (129) | (251) | (187) | (105) | (61) | (101) | (67) | +24.8% | ||||||
| Shareholders’ equity | — | — | — | 29 | 139 | 279 | 243 | 139 | 93 | 123 | 55 | +27.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (138.05) | (41.25) | (31.46) | (41.70) | (55.21) | (76.52) | (67.90) | (112.05) | +70.2 pt | |||||
| ROIC | — | — | — | (646.75) | (223.04) | (167.13) | (138.11) | (235.74) | (230.73) | (256.77) | 0.00 | +390.0 pt | ||||||
| ROE | — | — | — | 42.01 | 61.41 | (73.75) | (47.39) | (64.83) | (95.69) | (83.84) | (148.16) | (125.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 85 | 106 | 141 | 140 | 97 | 70 | — | (3.8%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Latest quarter Sep 2026 · fundamentals updated 6 Nov 2026
Tenaya Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NRXS Neuraxis, Inc. | $76.7M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| CLLS Cellectis S.A. | $74.5M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| OKYO OKYO Pharma Limited Sponsored ADR | $73.5M | — (loss-making) | — | — | n/m | +37.39% (above 0%: growing) | 0.00% | — | Compare |
| TNYA Tenaya Therapeutics, Inc. | $72.0M | — (loss-making) | — | — | n/m | −13.18% (below 0%: shrinking) | 100.00% | (1,153.33%) | |
| RANI Rani Therapeutics Holdings, Inc. | $72.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −55.29% (below 0%: shrinking) | 100.00% | (516.86%) | Compare |
| MNOV MediciNova, Inc. | $71.4M | — (loss-making) | — (loss-making) | +240.56% (above 0%: growing) | n/m | +16.75% (above 0%: growing) | 69.33% | (554.36%) | Compare |
| NTRB Nutriband Inc. | $67.8M | — (loss-making) | 4.6× | −29.72% (below 0%: shrinking) | n/m | +55.46% (above 0%: growing) | 41.58% | (203.57%) | Compare |
| ACRV Acrivon Therapeutics, Inc. | $67.3M | — (loss-making) | — | — | n/m | +12.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CSBR Champions Oncology, Inc. | $66.3M | — (loss-making) | — (loss-making) | +8.84% (above 0%: growing) | n/m | −198.74% (below 0%: shrinking) | 50.54% | (2.69%) | Compare |
| Median of peers | $71.7M | — | — | +4.42% | — | +14.67% | 59.94% | (203.57%) |
Pay and ownership Proxy statement filed 23 October 2026
Ownership
Directors and executive officers, together
2.69%
Entities affiliated with The Column Group
32.25%
Integrated Core Strategies (US) LLC
5.08%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement